Hey bear.. to expand on my question... if BP sees the potential of Apabetalone based on the BETonMACE trials.. they would estimate a return of x billion dollars...  however, if rvx was to start a new trial for non-diabetics and not cholesterol specific they could target a much bigger audience and realize potential returns of say xx billions..   is it fair to say that rvx would  keep the new targets for themselves... or would they want to hold off a sale till they start the new trial and raise expectations .. or is it not worth pursuing as Apabetalone would not be near as effective???